Search our Technologies
Find A Research Expert
Invest in our Startups
Find Out About our COVID-19 Technologies here

Available Technologies

The future is here
Yissum is the Technology Transfer company of The Hebrew University of Jerusalem. Our mission is to benefit society by converting extraordinary innovations and transformational technologies into commercial solutions that address our most urgent global challenges. We are leaders in innovation and experts in technology and evaluation acquisition strategies. Together with Hebrew University’s top researchers, Yissum is bridging breakthrough academic research with scientific and commercial applications.
Hebrew University Scientists at Forefront of mRNA Vaccination Revolution
“I read that CNN reported that US scientists suggested to extrapolate mRNA vaccines technology of COVID-19 for use in auto-immune diseases and cancers,” said Prof David Naor, the immunologist in question.
I realized that I had already done this more than 10 years ago, performing research that showed the potential for mRNA vaccines to combat autoimmune diseases and cancers.” Practically, we used cDNA vaccines, which were the first generation of mRNA vaccines, and they were efficient in the therapy of animal models of autoimmune diseases and cancer.
Yissum CEO discusses what it takes to run an Israeli Start Up

Dr. Itzik Goldwaser talks about his personal journey before becoming the head of Yissum. (Spanish)


Future Meat Technologies Ltd. is in talks with U.S. regulators to start offering its products in restaurants by the end of next year. The company has just opened what it calls the world’s first industrial cellular meat facility, which will be able to produce 500 kilograms (1,102 pounds) a day.
Future Meat Technologies, which has raised $43 million from investors including Tyson Foods Inc., Archer-Daniels-Midland Co. and S2G Ventures LLC, claims the lowest price for cultured chicken breast. It’s managed to cut the cost to $4 per 100 grams, a fraction of the original price, and plans to cut it by half again by the end of 2022, Kshuk said.

Success Stories